Abstract:Eukaryotic genomes are organized into hierarchical three-dimensional (3D) structure inside the nucleus, forming topological associating domains (TADs) and providing insulated neighborhoods for the highly interacting genome regions. These regions are established by potential chromatin bridging proteins, such as the cohesin complex and CTCF, forming loops. Within the framework of these TADs lie the loops defined by the transcriptional machinery, or RNA polymerase II (RNAPol II). Changes to this 3D genome structure are associated with the development of human diseases, including cancers. Prostate cancer (PCa), associated with transcriptional dysregulation, serves as an optimal model to understand the molecular mechanism behind the formation of dynamic loops between distant regulatory elements and their target genes in 3D space to regulate gene expression and cancer progression. This study integrates two protein-centric ChIA-PET data (RNAPol II and cohesin) with multiple ChIP-Seq data (CTCF, H3K27ac, AR and FOXA1), and RNA-Seq data of PCa cell lines (LNCaP, VCaP, DU145, and RWPE1) to perform promoter (P) centered analysis. Firstly, we investigated the proportions of RNAPol II loops with co-occupancy of cohesin peaks and vice versa to quantify and understand the involvement of these proteins in transcription regulation and validate them using simulations. The results supported the hypothesis that most RNAPol II loops were significantly enriched with cohesin peaks. However, the reverse was not true since inner RNAPol II loops enriched with cohesin regulate transcription, while most of the cohesin loops form long-range interactions, TADs. Further, we compared the correlation between the promoter centric RNAPol II-associated and cohesin-mediated interactions with gene expression. In the case of RNA Pol II mediated interactions, we found a quantitative increase in the strength of interaction between loci, this trend was not observed in cohesin mediated interactions, which were relatively stable. The only exception was in the cell line VCaP, possibly due to its genetic complexity, as the strength of interactions associated with Cohesin as well as RNA Pol II increased. We next examined if the strength of interactions between cohesin loops remains unaffected in the VCaP cell line when treated with dBET inhibitor. However, there was no significant difference observed. This explained that RNAPol II loops are more dynamic, whereas cohesin loops are more stable. However, whether the cohesin loops (internal and TAD boundary) stay stable in the active and inactive regions of the genome remains unexplored. Next, the study inspects how the cluster of regulated genes is organized, preferentially forming multi-gene complexes in PCa for efficient and potential cooperative transcription. We expect a significant role of super-enhancers in identifying interactions between key oncogenes in PCa, owing to cell-type specific biology. Highly co-regulated single- and multi-valent loops will be validated in the patient cohorts to establish significant correlations. Overall, this study enhances the knowledge of promoter-centric molecular mechanisms involved in multi-gene complex formation and coregulated transcription in PCa cell lines. Citation Format: Khyati Raghunath Chandratre, Susmita Ramanad, Ahmed abbas Elmahdi, Yunpeng Gao, Ram Shankar Mani, Michael Zhang. Landscape of promoter centric chromatin interactions and co-regulated gene network provide insights for transcriptional regulation in prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr LB011.

Abstract 3225: Profiling the DNA regulome to discover direct inhibitors of the brachyury transcription factor

Structures of the human transcription factor brachyury offer insights into DNA recognition, and identify small molecule binders for the development of degraders for cancer therapy

Development of a Covalent Small Molecule Downmodulator for the Transcription Factor Brachyury

Abstract 4311: Using multiomics analysis to identify dysregulated transcription factors in non-small cell lung cancer (NSCLC) to drive the expression of a cancer-activated synthetic biomarker

Abstract 2034: Discovery of novel therapeutic targets using 3D chromatin conformation and patient-specific gene regulatory networks

Small-molecule targeting of brachyury transcription factor addiction in chordoma

Abstract 3: Multiomics analyses reveal functional DNA, methylation pattern changes in clinical transgenic T-cell receptor cell therapy products

Abstract 5891: An image-based phenotypic screen identified CBP/p300 as new cancer drug resistance target and enabled the development of the clinical candidate TT125-802

Abstract 1694: Using high-throughput screening to identify DNA response elements that sense cancer dysregulated pathways

Abstract 6626: Functional and molecular interrogation of a high-plasticity cell state in lung cancer

Abstract B026: Chromatin Profiles Classify Castration-Resistant Prostate Cancers Suggesting Therapeutic Targets

Abstract 6496: Assessment of tyrosine kinase inhibitor bypass mechanisms in lung cancer using single cell multiomics, patient derived organoids and rationally designed drug screens

Abstract PO-012: Gain-of-function small molecules to reprogram oncogenic transcription in lymphoma

Abstract B042: A screen to identify modifiers of BRCA1 protein level for cancer prevention and treatment

Abstract 963: Comprehensive epigenomic profiling from plasma to inform therapy selection: A proof-of-concept study in cancer

Abstract A117: Molecular stratification of therapeutic targets in pancreatic cancer

Abstract LB011: Landscape of promoter centric chromatin interactions and co-regulated gene network provide insights for transcriptional regulation in prostate cancer

Abstract 2067: QUANTROseq, a transcriptomic based drug discovery platform using time-resolved gene expression profiling: Identification of inhibitors and degraders of transcription factors and cell signaling regulators

Abstract 680: Leveraging an RNA-targeting platform for the discovery of cell-active c-MYC mRNA-binding small molecules

Abstract SY11-02: Small molecule inhibitors of RNA modifying enzymes as precision cancer therapeutics

Abstract 2500: Technical feasibility of CRISPR-based functional profiling for solid tumor precision medicine